Latest Intellectual Property News

Wide Open Agriculture (ASX: WOA) has taken a significant step towards a capital-light production model by signing a non-binding framework agreement with Proeon Foods for contract manufacturing of its lupin-based ingredients, including exclusive Indian distribution rights.

Argent BioPharma's licensing partner Splash Beverage Group has launched the US veterinary development program for CannEpil®, targeting companion-animal oncology and chronic pain. Led by industry veteran Dr Hunter Land, the initiative follows a defined FDA regulatory pathway and could broaden CannEpil®’s commercial footprint beyond human neurology.

ION Video has boosted its cash runway by six months to December 2027 following a $612,498 capital injection from option exercises, while advancing commercial talks in the US.

Vitrafy Life Sciences reported an 80% revenue surge and halved its net loss, buoyed by US military validation and major blood network partnerships. A $32 million capital raise fuels its US commercial expansion and manufacturing scale-up.

Mayfield Group Holdings has finalized its acquisition of Nilsen's Switchboards Division, adding skilled staff and new product lines to boost manufacturing capacity and revenue growth prospects for FY27.

Singular Health deepens US healthcare foothold with ongoing Triple-S contract talks, PNS licence expansion, and Miami-Dade educational rollout, supported by a solid $10.1 million cash reserve.

Neurotech International has secured FDA clearance for its NTI164 Investigational New Drug application and obtained Notices of Allowance for two US patents, advancing its Phase 3 autism spectrum disorder program.

Spectur Limited posted its strongest quarter of cash receipts in FY26, driven by new contracts and a major technology upgrade, while launching legal action over significant customer losses.

Actinogen Medical’s pivotal XanaMIA Alzheimer’s trial stays on track for November topline results, buoyed by strong open-label extension enrolment and aligned EMA-FDA regulatory advice. A new antidepressant study publication and fresh patents add momentum, supported by a $16.7 million cash runway to mid-2027.

Island Pharmaceuticals has marked a major step forward in its antiviral program with the start of GMP manufacturing for Galidesivir, expanded USAMRIID collaboration, and FDA orphan drug designation. Regulatory approvals for compassionate use in Uganda’s Ebola outbreak and a new dose optimisation study with Texas Biomed further de-risk the pathway to approval.

The Calmer Co. has signed a binding heads of agreement with Kaiming Agro Processing to establish a long-term manufacturing partnership, leveraging advanced extraction technology in Fiji to scale its premium botanical ingredients business globally.

Streamplay Studio Limited has reported its fifth straight quarter of positive operating cash flow, driven by strong customer receipts and strategic publishing deals. The company is advancing multiple game releases and expanding its cloud gaming footprint across new regions.